Dorzolamide
Systematic (IUPAC) name | |
---|---|
(4S,6S)-2-ethylamino-4-methyl-5,5-dioxo-
5λ6,7-dithiabicyclo[4.3.0]nona-8,10-diene-8-sulfonamide |
|
Clinical data | |
Trade names | Trusopt |
AHFS/Drugs.com | monograph |
MedlinePlus | a602022 |
Pregnancy category |
|
Legal status |
|
Routes of administration |
Topical (eye drops) |
Pharmacokinetic data | |
Protein binding | ~33% |
Biological half-life | 4 months |
Identifiers | |
CAS Number | 130693-82-2 Template:CAS |
ATC code | S01EC03 (WHO) |
PubChem | CID: 5284549 |
IUPHAR/BPS | 6810 |
DrugBank | DB00869 |
ChemSpider | 4447604 |
UNII | 9JDX055TW1 |
KEGG | D07871 |
ChEBI | CHEBI:4702 |
ChEMBL | CHEMBL218490 |
Chemical data | |
Formula | C10H16N2O4S3 |
Molecular mass | 324.443 g/mol |
|
|
|
|
(what is this?) (verify) |
Dorzolamide (trade name Trusopt) is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent, and acts by decreasing the production of aqueous humour.[1] It is administered as a topical ophthalmic in the form of a 2% solution.[2]
History
This drug, developed by Merck, was the first drug in human therapy (market introduction 1995) which resulted from structure-based drug design. It was developed to circumvent the systemic side effects of acetazolamide which has to be taken orally.[2]
Uses
Dorzolamide hydrochloride is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension.
Pharmacodynamics
It lowers IOP by about 20%.[2]
Side effects
Ocular stinging, burning, itching and bitter taste.[2] it causes shallowing of the anterior chamber and leads to transient myopia.
References
- ↑ Dorzolamide at Drugs.com. Revised: 12/2011
- ↑ 2.0 2.1 2.2 2.3 Lua error in package.lua at line 80: module 'strict' not found.
Further reading
- Lua error in package.lua at line 80: module 'strict' not found.
- Lua error in package.lua at line 80: module 'strict' not found.
- Lua error in package.lua at line 80: module 'strict' not found.
- Lua error in package.lua at line 80: module 'strict' not found.